Synthetic cannabinoids (SCs) are herbal mixtures, which are sprayed with chemicals. Unlike naturally occurring marijuana, SC contains no tetrahydrocannabinol (THC), the pharmacologically active component of the marijuana plant. The SC was initially developed as anti-emetics for chemotherapy-induced nausea and other indications. However, in the late 2000s, recreational use of these compounds began in Europe. 1 Synthetic cannabinoids soon became widely available in the United States, where they were marketed and sold over-the-counter as "potpourri." In 2012, President Obama signed into law the Synthetic Drug Abuse Prevention Act, which banned 26 types of synthetic compounds, placing them under Schedule I of the Controlled Substance Act. 2 Despite this ban, hundreds of compounds continue to be manufactured and sold illegally, using countless pseudonyms (e.g., "Scooby Snax," "Annihilation," "Red Giant"). The lower cost ($5-10/g), as compared to marijuana ($10-40/g), contributed to their widespread adoption. In the last decade, the number of calls to poison centers for adverse effects of SC has significantly increased, with a geographic concentration in the Northeast. 3, 4 Physicians, pharmacists, and nurses practicing in emergency medicine and intensive care must be knowledgeable of the clinical presentation and possible treatment approaches for SC toxicity.
Multiple case reports have described severely altered mental status, seizures, fever, myocardial infarction, shock, rhabdomyolysis, and acute kidney injury (AKI) in patients with SC intoxication, but few reports have associated multiple organ failure with SC use, and only two have reported acute liver failure (Table 1) . [5] [6] [7] [8] [9] [10] [11] [12] We report a multicenter descriptive case series of six patients who presented with known SC use and were admitted for multiple organ failure between March 1, 2016, and July 19, 2016 , to the intensive care units of three hospitals in Maryland. Use of SC was determined by verbal report from the patient or a surrogate. Patients were followed to either discharge or death, and complications related to SC were documented.
Case Reports
All patients presented with altered mental status, and most were extremely combative to the point of requiring large doses of benzodiazepines or antipsychotics for patient and staff safety. In addition, all patients presented with severe rhabdomyolysis, with peak creatine phosphokinase (CPK) levels ranging between 4000 and > 320,000 units/L. Two patients required emergency lower extremity fasciotomies. Five patients presented with AKI, and four required continuous renal replacement therapy (CRRT). Most patients experienced fever (five of six patients). Myocardial injury, as evidenced by elevated troponin levels, occurred in three patients. Seizures also occurred in three patients. Three patients presented with shock requiring vasopressor support, and two patients developed fulminant hepatic failure that necessitated liver transplant evaluation. One patient required Molecular Adsorbent Recirculating System (MARS; Baxter International, Inc., Deerfield, IL) therapy as a bridge to successful transplant, and the patient without it did not survive. A short description of each patient presentation and hospital course is presented below and summarized in Table 2 . This was a postmortem analysis of synthetic cannabinoids present in serum. Deaths were attributed to synthetic cannabinoid intoxication but a detailed discussion of synthetic cannabinoids as a cause for injuries was not apparent.
status prompted intubation for airway protection, and he had a fever and a rapid onset of circulatory shock along with a marked lactic acidosis. He was also noted to have severe rhabdomyolysis with CPK peak of 236,769 units/L. Troponin was not checked. Within 24 hours of initial presentation, he developed fulminant hepatic failure, necessitating transfer to our referral hospital for transplant evaluation. He was treated with bilateral lower extremity fasciotomies for compartment syndrome, started on CRRT for AKI, and placed on MARS therapy as a bridge to orthotopic liver transplant while receiving Nacetyl-cysteine (NAC). Liver transplant was successful and the patient survived to discharge following a prolonged hospitalization.
Patient 2
Patient 2 was a 28-year-old recently incarcerated man who presented from an outside hospital after being found rolling around in the street by passersby. He self-reported K2 use to emergency medical services personnel. Urine toxicology was positive for cocaine, though his last time of use was unclear. Due to severe agitation, he was intubated for airway protection. He rapidly developed shock, profound lactic acidosis, fever, oliguric renal failure requiring CRRT, severe rhabdomyolysis with CPK peak > 320,000 units/L, and fulminant hepatic failure. His troponin peak was 2.17 ng/ml. He underwent emergency lower extremity fasciotomies due to compartment syndrome and was started on NAC therapy. He rapidly decompensated, and after discussion with family, life-sustaining therapies were withdrawn and the patient died.
Patient 3
Patient 3 was a 34-year-old woman who presented after being found unconscious at home by family 90 minutes after her last known well time. Upon arrival, she was agitated, combative, and febrile. Family confirmed likely SC use. She was intubated for airway protection. Urine toxicology was positive for methadone only, which was a prescribed medication for the patient. She was found to have rhabdomyolysis with CPK peak 6721 units/L and AKI requiring CRRT. Her peak troponin was 3.32 ng/ml. Her renal function recovered, she was extubated, and eventually discharged home.
Patient 4
Patient 4 was a 17-year-old male who presented after a driving an all-terrain vehicle in the street and striking a parked car at a high rate of speed. He sustained multiple lower extremity fractures, and upon arrival, an opened package of the synthetic cannabinoid "Scooby Snax" was found in his pocket. Urine toxicology was negative. He was promptly taken to the operating room for fracture reduction, at which time he was first noted to be febrile. Postoperatively, he remained intubated due to severe delirium and worsening hypoxemia. Out of concern for malignant hyperthermia, which later was genetically confirmed to be negative, empiric dantrolene was administered but ineffective. The patient developed severe rhabdomyolysis with a CPK peak around 16,000 units/L and AKI. His hospital course was complicated by pulmonary emboli and pneumonia, but he survived to discharge.
Patient 5
Patient 5 was a 32-year-old man who presented to the hospital complaining of auditory and visual hallucinations. He was initially admitted to a behavioral health unit but quickly became agitated, combative, and febrile. Urine toxicology was positive for cannabis. Due to concern for possible benzodiazepine withdrawal, he was given benzodiazepines but did not Patient 6 was a 47-year-old man who presented with a suspected asthma exacerbation. After admission, the patient left the hospital to smoke what he thought was marijuana but later suspected to be SC. He returned with respiratory distress that ultimately led to intubation. In under 24 hours, he developed unexplained shock, AKI with hyperkalemia necessitating initiation of CRRT, lactic acidosis, and severe rhabdomyolysis with peak CPK 23,571 units/L. His troponin was very mildly elevated to 0.167 ng/ ml. He eventually underwent tracheostomy in the setting of his underlying obstructive lung disease and failure to successfully wean from mechanical ventilation. His renal function eventually recovered and he was discharged after a prolonged hospital stay.
Discussion and Literature Review

Practical Considerations and Limitations
A unique challenge of these compounds is the inability to test for them on traditional urine toxicology screens. Because SC does not contain THC, a positive or negative THC screen neither confirms nor excludes SC use. Currently, detection by liquid chromatography with mass spectrometry is the optimal laboratory test for confirming SC use, but results are generally not available for several days. To further complicate testing, identification of SC is limited by the lack of availability of pure reference samples, and large amounts of vitamin E often are sprayed on the material to mask analysis of the SC. Batch-to-batch variability of SC concentration is another confounding factor. 13, 14 Consequently, while reports of SC intoxications are increasing nationwide, confirmation of SC ingestion is largely by self-report or report by family and friends. Aside from laboratory confirmation, patient self-report of ingestion is the next best way to confirm use of SC, but that is often impractical in a patient with mental status changes. In this case series, we obtained verbal confirmation of SC ingestion from family members or friends, which is a frequent scenario in clinical practice. We also recognize that in patients presenting with drug intoxication, there are frequently multiple drugs of abuse involved, as was likely the situation in this case series. Given the overlap in the clinical presentation of different intoxication and withdrawal syndromes, it can be challenging to discern the true etiology of different aspects of the patient's signs and symptoms. Nonetheless, the six cases of multiple organ failure we report here were all assessed based on clinical judgment to be primarily related to SC toxicity.
Mechanism of Toxicity
Synthetic cannabinoids are potent agonists at the cannabinoid receptors CB1 and CB2, which are G protein-coupled receptors of the endocannabinoid system. The 4-to 10-fold greater affinity for these receptors compared with THC is the postulated reason for their negative physiologic effects. 15 Continued research seeks to further our understanding of cannabinoid receptor activation in various organ systems.
The CB1 receptor population is quite dense in the brain, particularly in the basal ganglia, hippocampus, cerebellum, and cerebral cortex. 16 These receptors are expressed by presynaptic glutamatergic or GABAergic neurons, with a higher concentration on GABAergic neurons. Activation of these receptors leads to decreased glutamate or GABA release, which in turn results in reduced excitation or suppressed inhibition, respectively. Suppressed GABA-mediated inhibition then excites the postsynaptic cell. Interestingly, the CB1 receptors are not only located in the brain but also in the heart, kidneys, liver, and other organs. [17] [18] [19] The CB2 receptors are also present in the brain (although not as densely as the CB1 receptor) but are more significantly expressed by hematopoietic and immune cells. Activation of CB2 receptors in the immune system leads to down-regulation of cAMP, ultimately suppressing cytokine release, and promoting an antiinflammatory effect. Interestingly, these receptors are also located in the kidney, and a substantial amount of research is under way examining potential nephroprotective effects associated with CB2 activation. 20 
Clinical Presentation
Multiple organ system failure was present in all patients with SC intoxication in this case series. Altered mental status, rhabdomyolysis, AKI, and fever were common. Shock, myocardial injury, and seizures were less common but have been previously described in multiple case reports and case series. Fulminant hepatic failure has been rarely reported, and to our knowledge, only three other reports of this complication have been documented. 6, 10 As previously stated, the psychogenic effects seen in these patients are postulated to be secondary to CB1 activation in the brain by such potent agonists with significant receptor-binding affinity. In addition, a dose-dependent effect cannot be excluded.
Synthetic cannabinoid-associated AKI has been frequently described in the literature, and five of our patients developed this complication, with three being severe enough to require CRRT. Of these three, two survived and renal function recovered. Researchers reported on four patients with AKI after SC use, and three of these patients had renal biopsies consistent with acute tubular necrosis. 5 The Centers for Disease Control and Prevention reported 16 cases of AKI associated with SC use in 2012, and six renal biopsies were consistent with ATN while three showed evidence of acute interstitial nephritis. 11 Another group showed that CB1 expression was higher in renal biopsies of patients with various nephropathies and that knockout mice for CB1 resulted in a significant reduction of renal fibrosis. Although the exact mechanism has not been established, renal CB1 activation stimulates myofibroblastinduced renal fibrosis. 21 We therefore postulate that AKI may result from renal CB1 activation. However, pigment nephropathy in patients with severe rhabdomyolysis or direct nephrotoxicity on the molecular level is also possible.
Rhabdomyolysis in patients with SC intoxication has been a common finding in many case reports and case series. [7] [8] [9] 12 In most reports, the mechanism was postulated to be the patients' severe agitation, fevers, or seizures. However, we noted this complication in all of our patients, despite the lack of extreme agitation (e.g., several patients were found obtunded), fevers, or seizures. While these factors can certainly contribute to the development of rhabdomyolysis, we propose that SC may have direct myotoxicity, similar to a drug like propofol. On a molecular level, propofol is toxic to mitochondria and elevates malonyl-carnitine levels, uncoupling the ability to undergo oxidative phosphorylation, and thereby inhibiting the respiratory chain. In addition, host factors may play a role in the development of rhabdomyolysis, similar to how inherited disorders of glycogenolysis, glycolysis, or lipid metabolism, as well as genetic polymorphisms that impair mitochondrial pathways can predispose to rhabdomyolysis. 22 Similar to a "two-hit" hypothesis of DNA injury, host factors such as these, coupled with the potential myotoxicity of SC, could injure the skeletal muscle, but these mechanisms remain to be investigated. Acute liver failure is a rarely described complication associated with SC intoxication, and our single patient to survive this complication required an orthotopic liver transplant. A case of SC-induced hepatitis treated successfully with NAC was described, suggesting that the mechanism of hepatic injury may be related to depleted mitochondrial and cytosolic glutathione stores, as well as free oxygen radicals. 10 Figure 1 summarizes the current understanding of how SC toxicity causes organ injury that results in the clinical presentation of these patients. Identifying the key clinical characteristics and maintaining a high index of suspicion for the diagnosis of SC toxicity helps determine optimal organ-specific management pathways to ultimately yield improved patient outcomes.
Conclusions
We describe a multicenter case series of six patients admitted with SC intoxication displaying similar symptoms and sequelae, all resulting in multiple organ failure. Reports of multiple organ failure, and hepatic failure in particular, associated with SC toxicity are rare. We describe the first report of a patient with hepatic failure requiring MARS and liver transplantation. Given the growing abuse of these substances, clinicians should consider SC ingestion in the differential of such patient presentations. More investigation is needed to elucidate the mechanisms associated with SC toxicity in an effort to design therapeutic anecdotes and optimize supportive care of these patients.
